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Abstract
Background: Individuals with type 2 diabetes (T2D) who smoke are at increased risk for many types of cancers as
well as an accelerated progression of microvascular and macrovascular complications. Smoking cessation is
recommended as a standard treatment for T2D; however, individuals with T2D are faced with competing lifestyle
changes. Glycemic and blood pressure control often take precedence over smoking cessation, and patients are
often unmotivated to quit. Contingency management in combination with standard smoking cessation treatment
has been demonstrated to improve cessation outcomes in various populations. The purpose of this randomized
controlled feasibility trial is to explore the feasibility of contingency management and biochemical verification using
a remote smartphone-based carbon monoxide monitor for smoking cessation among individuals with T2D.
Methods: A three-arm, randomized controlled feasibility trial will be conducted in two study sites that include the
USA and UK. We will recruit 60 participants who will each receive usual care smoking cessation treatment
(counseling and nicotine replacement therapy) and be randomized to a short term incentives (6 weeks), long term
incentives (12 weeks), or no incentives (control) group. Participants will receive a smartphone and carbon monoxide
monitor to complete daily remote assessments throughout the 12 weeks and will complete an exit interview at the
end of the study. The primary outcomes for this feasibility study include completion of the protocol and proportion
of daily assessments completed. Secondary outcomes include recruitment measures, acceptability, and smoking
abstinence.
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Discussion: We will explore the feasibility of recruiting smokers with T2D and their engagement in the program,
particularly related to the use of the remote biochemical verification and smartphone application. In addition, we
will evaluate the intervention content, study procedures, data collection methods, and follow-up and will
qualitatively assess the participants’ acceptability of the program. The results of this study will inform the design of
a larger trial to test the efficacy of the contingency management program for improving smoking cessation
outcomes among individuals with T2D.
Trial registration: This randomized controlled feasibility trial has been registered at ClinicalTrials.gov with an ID
NCT03527667 on May 4, 2018.
Keywords: Smoking cessation, Diabetes, Financial incentives, Contingency management, mhealth
Background
Type 2 diabetes (T2D) and cigarette smoking are major
causes of morbidity and mortality in the USA (US) and
United Kingdom (UK) [1–5], and research indicates
there is a complex relationship between these two risk
factors [6–10]. Smoking is a major behavioral risk factor
for many types of cancer, is associated with insulin re-
sistance, and was listed as a causal factor for T2D in the
2014 Surgeon General’s Report [4, 6, 11]. The harms of
smoking are particularly profound among individuals
with T2D who continue to smoke, with an accelerated
progression of microvascular and macrovascular compli-
cations and an increased mortality risk [7, 8, 12]. Indi-
viduals with T2D are also independently at increased
risk for many cancers, although the link between T2D
and cancer is currently not well understood [13, 14]. Evi-
dence suggests biological mechanisms along with in-
creased prevalence of behavioral risk factors play a key
role [6, 14–16]. Despite the heightened risk for cardio-
vascular disease, cancer, and diabetes-related complica-
tions, many patients with T2D continue to smoke. As
the prevalence of T2D in the US and UK population is
expected to double in the next three decades, it is essen-
tial that we understand the impact of smoking on dia-
betes and health outcomes and identify ways to
effectively integrate smoking cessation into diabetes care
[5, 17].
As standard care, those diagnosed with diabetes who
smoke are recommended by the American Diabetes As-
sociation and the UK’s National Institute of Health and
Care Excellence to stop smoking; however, patients with
T2D and their providers are often inundated with other
challenging lifestyle changes and disease management
strategies [18, 19]. Glycemic and blood pressure control
through dietary changes often take precedence over ces-
sation, and patients often feel unmotivated or are unable
to quit smoking [19]. Due to the complex relationship
between T2D and smoking and the large number of
competing lifestyle changes recommended at diagnosis,
smokers with T2D may benefit from a program that in-
centivizes smoking cessation.
Providing patients with tangible rewards to reinforce
positive behaviors, such as smoking abstinence, has been
proven effective during treatment in substance abuse pro-
grams, smoking cessation programs among pregnant
women unwilling or unable to quit, and other population
subgroups [1, 20–24]. Contingency management, or the
exchange of a reward contingent upon verified smoking
abstinence, in combination with standard smoking cessa-
tion treatment, has been demonstrated to improve cessa-
tion outcomes in various populations [1, 20, 24–29]. Few
studies have examined the effects of a contingency man-
agement program or financial incentives for smoking ces-
sation among individuals with chronic disease [30].
Through a retrospective analysis of randomized trials,
Walter and Petry demonstrated that participants with dia-
betes responded well to contingency management as a
treatment for substance abuse and that the effect of the
incentives was greater than for individuals without dia-
betes [31]. Other studies among patients with diabetes
have focused on contingency management for diabetes
medication adherence [32, 33]. Despite the heightened
risks of smoking-related outcomes among individuals with
T2D, to our knowledge, contingency management has not
been tested in this population as a smoking cessation
intervention. It is unclear whether a contingency manage-
ment program would be feasible and acceptable in this
population.
The need to biochemically verify smoking abstinence
daily creates a challenge for many contingency manage-
ment programs for smoking cessation. Smoking abstin-
ence is primarily verified through saliva, urine, or carbon
monoxide (CO) assessments, but challenges around the
costs, difficulty of administration, and logistics of daily
testing has been a limiting factor in contingency man-
agement studies [26, 34]. Researchers have had to
choose whether to place the burden of many in-person
visits on the participants or incur significant data collec-
tion costs through daily home visits by study coordina-
tors. With the rapid expansion and development of
mobile health (mHealth) technology, there are now
smartphone-based remote CO sensors that can be
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distributed to each research participant for daily verifica-
tion of smoking abstinence [27, 34–36]. In addition, the
combined use of a smartphone sensor and application
(app) provides the opportunity for daily assessment of
urges to smoke, motivation to quit, tobacco use, and
medication adherence. If ultimately proven feasible and
effective, this remote smartphone approach also provides
a scalable and cost-effective means of delivering this
intervention in a healthcare setting.
Study aims and hypotheses
The research objectives and trial design were conceived
and developed through a unique multidisciplinary and
international collaboration formed during a knowledge in-
tegration sandpit event hosted by the US National Cancer
Institute and Cancer Research UK. This was a residential
workshop bringing together investigators from the UK
and the US across different sectors and disciplines (e.g.,
academia, technology, epidemiology, psychology, commu-
nity) to integrate knowledge about behavioral cancer risk
factors, form new networks, and develop innovative re-
search grant proposals in cancer prevention. Through this,
we designed a randomized controlled feasibility trial to ex-
plore the acceptability and feasibility of a contingency
management program for smoking cessation among
smokers with T2D previously unable to quit. This pilot
study aims to gather data in both the US and UK context
related to the feasibility of conducting a contingency
incentive-based program with remote biochemical verifi-
cation using a smartphone-compatible CO monitor. This
study explores two different lengths of contingency man-
agement (6 weeks vs 12 weeks) for this population using a
smartphone app and remote CO sensor to monitor urges
to smoke, stressors, smoking behaviors, and to validate ab-
stinence daily throughout the intervention. The specific
aims of the study are to:
1. Explore the feasibility of conducting a randomized
controlled trial to compare the effect of two
different contingency structures ($20 or £15 weekly
incentives for 6 weeks vs 12 weeks) vs control (no
incentives) on smoking abstinence.
2. Explore the feasibility of remote CO testing using a
smartphone-based CO sensor and mobile app to
validate abstinence.
3. Gather preliminary evidence and estimates of
recruitment and eligibility rates, loss to follow-up,
as well as the likely effect size of the intervention on
smoking cessation to inform parameters of a large
randomized controlled trial.
4. Examine the acceptability of the intervention
content, delivery mode, timing, adherence, and
maintenance.
5. Explore the potential unintended consequences
(e.g., weight, glycemic control, perceived health) of
the intervention.
Methods/design
Study design
A three-arm, randomized controlled feasibility trial will
be conducted in two study sites that include the US
(Oklahoma City, Oklahoma, USA) and UK (Greater
Glasgow, Scotland, UK). The US site is located at the
University of Oklahoma Health Sciences Center
(OUHSC) campus within the Tobacco Treatment Re-
search Program that is a part of the Oklahoma Tobacco
Research Center. This clinic provides in-person and tele-
phone cessation services to the metropolitan area as well
as surrounding towns. The UK site is located at the Uni-
versity of Strathclyde and Stop Smoking Services clinics
located in Glasgow and Ayrshire and Arran.
This trial will include a baseline assessment (visit 1),
quit date visit that occurs 1 week after the baseline as-
sessment (visit 2), and a third follow-up visit (visit 3) at
the end of the 12-week cessation program, or 13 weeks
after the baseline visit. The participants will complete 12
total weeks of daily assessments using a smartphone be-
ginning on the quit date (visit 2). The 12-week post-quit
follow-up period coincides with the 12 weeks of nicotine
replacement therapy (NRT) that participants are eligible
to receive as part of their standard smoking cessation
services.
Participant eligibility and recruitment
We aim to recruit 30 current smokers with T2D at each
study site (N = 60), with 10 in each arm of the study at
each location. This sample size is based on our primary
feasibility outcomes and sufficient for determining com-
pletion of the study protocol and adherence to daily as-
sessments. Eligibility criteria for study enrollment
includes adults aged 18 to 75, diagnosed with T2D at
least 1 year prior to enrollment, current smoking inten-
sity of at least 5 cigarettes per day, and a self-reported
quit attempt in the past 12 months indicating that they
had previously been unable to quit. Participants will be
excluded from the study if they are unwilling to make a
quit attempt through the usual cessation care program
or are unwilling or unable to use the smartphone and
CO monitor following a brief training session.
Participants will be recruited opportunistically in both
the US and the UK through multiple avenues, including
T2D clinics using physician referrals and clinic flyers,
adult smoking cessation services, diabetes support
groups, newspaper and online advertisements, posted
and emailed recruitment flyers, posters in health and
University settings, recontact of research participants in-
terested in future research, and word of mouth.
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Interested individuals who meet the inclusion criteria
will be given an information pack so they can contact
the researcher directly to discuss participation. A follow-
up appointment will be made for those who choose to
participate where eligibility will be checked and in-
formed consent taken.
In the US, this study will be integrated into the current
protocol for standard smoking cessation services at the
Oklahoma Tobacco Research Center’s (OTRC) Tobacco
Treatment Research Program. Individuals who call dir-
ectly to the smoking cessation clinic or who are referred
to the clinic through electronic medical record referral
will be screened for eligibility. Any smoker interested in
quitting and eligible for this study will be provided infor-
mation about the study and the opportunity to partici-
pate at their initial smoking cessation appointment.
Intervention and control groups
Participants will be randomized to one of three groups:
(1) a short-term (6 weeks) incentives group, (2) a long-
term (12 weeks) incentives group, and (3) a control
group with no incentives. Participants in all three study
arms will receive the usual smoking cessation care avail-
able in each setting. Usual care in both sites will include
an in-person or telephone counseling component, se-
lected by the participants, for at least a 6-week period as
well as NRT and/or medications for a 12-week period.
Due to the limitations of the small feasibility study and
the reliance on existing treatment programs for usual
care, we will not be able to completely standardize the
cessation components in both countries. However, we
will explore adjustment for treatment intensity including
counseling sessions completed and NRT received during
the analysis through multivariable modeling to account
for differences in usual care received.
The incentives groups will have the opportunity to
earn $20 or £15 per week by providing evidence of
smoking abstinence using remote CO monitors. We will
validate smoking abstinence via remote biochemical
verification through the use of the CoVita iCO™ Smoker-
lyzer® breath monitor, which is a personal and remote
CO sensor that plugs directly into a smartphone [37].
The iCO™ Smokerlyzer® has been demonstrated to be
highly reproducible and able to differentiate between
smokers and nonsmokers; however, results consistently
differ slightly suggesting a need for calibration guidelines
[38]. The OTRC has internally evaluated the validity and
reliability of the iCO™ Smokerlyzer® integrated into the
INSIGHT™ application by testing known concentrations
of CO at 5 ppm, 10 ppm, and 20 ppm and found that
multiple iCO™ Smokerlyzer® sensors were consistent and
accurate enough to differentiate smokers from non-
smokers. Evidence of abstinence each week will be de-
fined as 5 out of 7 days (> 70%) with CO readings of less
than 8 parts per million (ppm) submitted through the
remote CO sensor. Participants in the short-term incen-
tives program will be eligible to earn weekly incentives
for the first 6 weeks of the program, or only during the
counseling portion of the usual care program.
Participants in the long-term incentives program will be
eligible to earn weekly incentives throughout the full
duration of the 12-week usual care cessation program,
which is the length of time they are eligible to receive
NRT as part of usual care. Participants in both
incentives groups will be notified weekly about incen-
tives earned throughout the duration of follow-up, and
earned incentives for both groups will be distributed in
the form of gift cards at the end of the 13 week study
(visit 3) following the return of the smartphone. Each
weekly incentive is independent and does not require
continuous abstinence throughout the entire incentive
period. All three groups will be instructed to submit
daily assessments for the duration of the 12-week pro-
gram. Individuals in the control group will be unable to
earn incentives and will not be compensated for their
participation in the research study due to restrictions of
the charity funding source. This is common in the UK
and is not anticipated to be a problem. However,
participants in the US are often compensated for re-
search. Therefore, individuals in the US control group
will be informed that they are eligible to win a tablet
computer when they complete the 12-weeks and return
the study phone.
Randomization
Participants in this unblinded study will be randomly al-
located to one of the three groups based on block
randomization. A random number sequence generated
by a computer will be created, which will then be used
in the randomization feature in Research Electronic Data
Capture (REDCap). After an individual provides in-
formed consent at the baseline visit (visit 1), the partici-
pant will be asked to return for the quit date at visit 2 1
week later. Prior to visit 2, a study coordinator without
prior knowledge of the sequence will randomize the par-
ticipant via REDCap, allocate the individual to the se-
lected group, and inform the participant of their
assigned group at visit 2. Participants will be informed of
their assigned group at the second visit in attempt to
maximize the likelihood of continuation in the study for
individuals who are assigned to the control group and
unable to earn incentives. In addition, the control group
participants in the US will be reminded of their 1 in 10
chance of winning a tablet after completing the
study. Blinding throughout the duration of the study is
not feasible because the notification of each weekly
earned incentive is part of the intervention.
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Data collection and outcome measures
Assessments of study measures will be obtained at each
of the three in-person visits (Week 1, 2, and 13) as well
as through a daily assessment using a smartphone that is
provided to each participant (Table 1).
Assessments at visits 1, 2, and 3
At all three in-person visits that will occur in the treat-
ment clinics, biological/anthropometric measures will be
collected by the research coordinator and entered into a
secure REDCap database. These measures include
height, weight, and tobacco use status measured through
expired CO using a Vitalograph Breath CO monitor. At
visits 1 and 3, additional measures will be obtained
through self-administered surveys in REDCap using a
tablet. Participants will complete 10 items related to
demographics, which include sex, age, race/ethnicity,
marital status, education, employment status, income,
and the status of whether the participant lives with a
smoker, has an active mobile phone, and if it is a smart-
phone. We developed a tobacco use history question-
naire that will capture 17 items related to current and
past product, dose, and duration of use of tobacco, quit
attempt history, perceptions of harm, comorbidities, and
medication use. To assess dependence, participants will
complete two items from the heaviness of smoking index
[39] as well as 4 items from the Wisconsin smoking
withdrawal scale for craving [40], both of which have
been shown to be valid and reliable. We will use a 9-
item self-efficacy scale/confidence to reflect the
Table 1 Detailed data collection schedule and measurement items
Study period
Enrollment (-t1) Allocation (0) Post-allocation
(t1-t12)
Close-out
(t13)
Assessment
items (#)
Visit 1 (baseline,
week 1)
Visit 2 (quit date,
week 2)
Daily assessment
(week 2 to 13)
Visit 3
(week 13)
Enrollment
Eligibility screen X
Informed consent X
Allocation X
Interventions
Short term incentives (6 weeks) X X X X
Long term incentives (12 weeks) X X X X
No incentives (control) X X X X
Assessments
Biological/anthropometric measures 3 X X X
Demographic/background information questionnaire 10 X
Tobacco history questionnaire 17 X
Heaviness of smoking index 2 X
Wisconsin smoking withdrawal scale—craving (past week) 4 X
Self-efficacy scale/confidence 9 X
Motivation to quit 3 X
Diabetes questionnaire 5 X
Diabetes self-management questionnaire 16 X X
Consideration of future consequences scale 12 X
Daily stress and anxiety 5 X
Daily urges to smoke 4 X
Daily mood and physical symptoms scale 12 X
Daily self-efficacy/confidence/motivation 4 X
Daily tobacco and medication use 7 X
Daily diabetes and health questions 6 X
Daily CO reading (iCO™ Smokerlyzer®) 1 X
Study participation exit questionnaire 10 X
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confidence that they can cope with high-risk situations
without relapsing as well as 3 items assessing motivation
to quit [41]. In addition to tobacco-related questions,
participants will respond to diabetes-related question-
naires, which include a 5-item section related to age of
diagnosis, diabetes control, and glycated hemoglobin and
a 16-item diabetes self-management questionnaire asses-
sing self-care activities related to diabetes [42]. Finally,
we will collect measures of delayed gratification using
the 12-item consideration of future consequences scale
[43]. Table 1 outlines the assessments and number of
items during the in-person visits.
Daily assessments
Beginning at the quit date at week 1 throughout the dur-
ation of the 12-week intervention, we will use mobile-
based daily assessments to validate abstinence and cap-
ture additional data related to stress and anxiety, urges
to smoke, mood and physical symptoms, self-efficacy
and confidence, motivation, tobacco and medication use,
and diabetes information (Table 1). Daily assessments
will be collected through the INSIGHT™ mobile health
platform developed by OTRC [44]. We will purchase a
Samsung Galaxy S7 phone in the US and a Samsung J3
Prime phone in the UK along with a 3-month data plan
for each participant. Each participant will also receive a
CoVita iCO™ Smokerlyzer® sensor to use throughout the
study period. Using a smartphone application platform
developed by the OUHSC OTRC mHealth Core, we pro-
grammed an app to collect our specific daily measures.
The app will be installed onto the study phones and par-
ticipants will be prompted through an evening alarm to
submit daily CO readings (in ppm) and complete the
daily assessment throughout the study period. The
OUHSC mHealth Core has integrated the CO sensor
into the platform with step-by-step instructions within
the app that will collect assessment data so that partici-
pants will submit all measures in one cohesive
assessment.
The daily assessment, estimated to take between 5 and
10min, will begin with the CO reading followed by 5
items related to daily stress, which include the validated 4-
item perceived stress scale [45]; 4 items assessing daily
urges to smoke; the validated 12-item mood and physical
symptoms scale [46]; 4 items related to self-efficacy, confi-
dence, and motivation to quit; tobacco use, including
products used, amount, and cessation medications; and 6
items related to diabetes management, which includes
self-rated health, diabetes control, healthy food choices,
and physical activity. Study coordinators will monitor
compliance to daily assessments and will reach out to par-
ticipants who quit completing assessments to encourage
them to continue completing assessments.
Exit surveys and interviews
At visit 3, participants will complete a brief exit survey
that includes 10 questions related to their experience in
the study. Participants will be asked to rate the difficulty
or ease of using the smartphone, the app, and the CO
device and about their perception of accuracy of the CO
readings. They will be asked about reasons for missing
daily assessments, the difficulty or ease of this quit at-
tempt, whether payments may have helped them or
could help others to quit, and if they were honest and
completed the assessments themselves as instructed.
The qualitative interviews will use semi-structured topic
guides to gather rich and in-depth information related
to the participants’ motivation to take part in the study,
their attitudes towards financial incentives, their experi-
ences in the study submitting data, their overall quit at-
tempt, any perceived impact on their diabetes, and
suggestions for improvements to the study. The inter-
views will be carried out in-person or over the telephone
according to the participant’s preference and every par-
ticipant will be approached for recruitment for an inter-
view. The interviews will be audio-recorded and
transcribed verbatim.
Feasibility outcome measures
As this is a feasibility study, our primary outcomes will
be the completion of the study protocol and proportion
of daily assessments completed. Our secondary out-
comes for the feasibility study will be monthly recruit-
ment rates and participants’ acceptability of study
procedures as measured in the exit survey and qualita-
tively in the exit interviews. Although this pilot study is
underpowered to detect differences in cessation between
groups, we will also measure and explore differences in
the outcomes that would be used in a larger randomized
controlled trial: continuous abstinence at 12 weeks, time
to relapse, and cigarettes per day throughout the study
period.
Study procedures
At visit 1, the study coordinator will demonstrate the
use of the smartphone and remote CO device and an-
swer any questions related to the study procedures. After
obtaining informed written consent, the study coordin-
ator will measure height, weight, and CO and the par-
ticipant will complete the baseline assessments using a
REDCap survey on a tablet. At visit 2, 1 week after base-
line, the participant will return to the clinic on their quit
date. A study coordinator will provide instructions to
the participant based on their random group assignment
and will provide the participant with their smartphone
and CO monitor. The participant will receive written in-
structions and training on how to use the smartphone
and respond to the daily assessments. Participants will
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receive a 300-min unlimited data and text phone plan
and will be permitted to use the phone for calls, text
messages, and internet during the 12-week follow-up
period to encourage participants to ensure the phone is
charged and available at the time of each assessment.
This will also be an incentive to submitting data since
we are unable to compensate participants for submitting
data. Participants will be asked on their preferred
method of contact, which includes calls or text messages
on their study phone or personal phone. A study coord-
inator will monitor their data weekly and contact partici-
pants throughout the 12-week daily assessment follow-
up period to ensure that the phone is working and to
answer any questions. Participants who enroll in the
study at the baseline visit who miss their quit date and,
therefore, do not receive a smartphone or CO monitor
will be involuntarily withdrawn from the study if they
are not able to reschedule within 1 week. Participants
who wish to withdraw from the study at any time will be
asked to return the smartphone and will be voluntarily
withdrawn at the time of the request. Participants who
withdraw from the study are offered the opportunity to
provide feedback on the study prior to exiting. At visit 3,
participants will complete the exit survey and exit inter-
view and return the study phone and CO device to the
study personnel.
Statistical methods
As this is a feasibility study, we will first examine our
primary outcomes by calculating loss to follow-up rates
for the follow-up visits and the proportion of daily as-
sessments completed per participant for each study arm.
We will also examine monthly recruitment and enroll-
ment rates, and evaluate the acceptability of the program
using the exit survey items. Although we are underpow-
ered to test differences, we will explore the feasibility of
our study protocol and data completeness by conducting
statistical analyses similar to that of a larger trial. We
will initially conduct range checks for data values to as-
sess data quality. We will calculate descriptive statistics
and compare baseline characteristics between arms to
ensure adequate randomization between groups. All
questionnaire items will be scored using methodology
described in the literature. We will calculate means and
standard deviations for continuous measures and fre-
quencies for categorical measures. We will use time-to-
event analysis to explore time to relapse and/or time to
discontinuing the daily assessments. Smoking cessation
assessment data and ecological momentary assessment
data will be measured repeatedly and will therefore be
correlated within subjects. Thus, our analytic approach
will include generalized linear mixed model regression
analysis. This analysis approach can handle normal and
non-normal outcomes, such as dichotomous smoking
status variables, different variance functions, as well as
unbalanced designs where the number of repeated ob-
servations varies across individuals. Analyses will be con-
ducted using both intention-to-treat and per-protocol
approaches. All preliminary results will be inter-
preted with caution and treated as preliminary due to
small numbers in each arm of this feasibility study. For
the qualitative components of this study, we will use the
transcribed interviews to develop codes and we will use
thematic analysis to determine the feasibility and accept-
ability of this study protocol.
Ethical considerations and dissemination policy
This study protocol outlined in Table 2 has been
reviewed and approved by the University of Oklahoma
Health Sciences Center Institutional Review Board (IRB#
8652) as well as the NHS Welsh Research Ethics Com-
mittee, (IRAS ID 231008). Each participant will provide
informed written consent prior to enrollment. Partici-
pants will be assured that their participation is voluntary
and that they have the right to withdraw at any time.
They will also be informed that choosing not to partici-
pate will not affect their receipt of standard smoking
cessation services. Anonymized and aggregated findings
will be presented at conference and submitted for publi-
cation in academic peer-reviewed journals.
Discussion
Diabetes management is complex, and individuals with
T2D are often encouraged to change multiple behaviors,
such as diet, exercise, glucose monitoring, and medica-
tions. Smoking cessation is an important behavior modi-
fication that is recommended for individuals with T2D,
but cessation often competes with other lifestyle modifi-
cations that take precedence and individuals with T2D
often struggle to quit. This feasibility study aims to ex-
plore novel ways of improving the smoking cessation
outcomes among individuals with T2D through contin-
gency management. As this is a feasibility study, we will
explore the ability to recruit smokers with T2D who are
interested in quitting and measure their engagement in
the program, particularly related to the use of the re-
mote biochemical verification using a smartphone app.
In addition, we will evaluate the intervention content,
study procedures, data collection methods, and follow-
up and will qualitatively assess the participants’ accept-
ability of the program, including the duration of the
daily assessments. While it is unclear what duration of
daily assessments will be acceptable to this study popula-
tion, other studies have used daily assessments for a
wide range of durations with success [47]. We have lim-
ited our daily assessment to one brief assessment per
day at the time of the participant’s choice to minimize
burden throughout the 12-week period.
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As this study was developed through a unique multi-
disciplinary collaboration between investigators in the
US and UK, this protocol was designed to account for
cultural differences between the two sites. We included
subtle differences across sites in regards to recruitment
methods, questionnaire items, the cell phone and data
plans that will be provided, the amount of incentives
that can be earned, and the integration of our study
protocol into the local standard cessation services. In
designing the protocol, we discovered cultural differ-
ences in the expectation of compensation for the par-
ticipation in research. In the US site, community
members are often provided compensation for engaging
in research studies, whereas participants in the UK are
not routinely offered compensation for research carried
out in publicly funded healthcare settings. To account
for differences in motivation to participate in research
that might pose potential difficulties in recruitment or
the engagement of controls in the US, we added a
chance to win a tablet for the control group in the US
site. Although there is a concern that there might be
differential drop out in the control group due to the in-
ability to earn incentives or be compensated for sub-
mitting data, this is a feasibility study and this will be
evaluated as part of acceptability and feasibility mea-
sures. The protocol also included two similar versions
of the study assessments that accounted for cultural
and language differences, with subtle variations in the
response options on survey items, such as race and eth-
nicity, employment and income.
Overall, this unique international and multidisciplinary
protocol will provide an opportunity to examine the
feasibility of using mobile technology and financial in-
centives to increase the success in quitting smoking
among a population that faces many critical lifestyle
changes that undermine motivation and perceived cap-
ability for quitting. With T2D and other chronic condi-
tions on the rise, it is important to explore new ways of
addressing smoking cessation for patients with multiple
behavior change priorities.
Table 2 World Health Organization trial registration data set
Data category Information
Primary registry and trial identifying number ClinicalTrials.gov, NCT03527667
Date of registration in primary registry May 4, 2018
Secondary identifying numbers N/A
Source(s) of monetary or material support Cancer Research UK
PO Box 1561
Oxford OX4 9GZ
Phone: 0300 123 1022
Primary sponsor Cancer Research UK
Secondary sponsor(s) Stephenson Cancer Center
Contact for public queries Sydney Martinez, PhD (405)271-2229, sydney-martinez@ouhsc.edu
Contact for scientific queries Sydney Martinez, PhD (405)271-2229, sydney-martinez@ouhsc.edu
Public title Incentivized smoking cessation for diabetics
Scientific title Incentivized smoking cessation for tobacco treatment-resistant diabetics
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